-
11:48:29 PM

IMMX Stock News

09/21/23 8:55 AM
Nasdaq : IMMX
clinical trialfda approvallow float
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified clinical testing Waiver of the Prescription Drug User Fee (currently at almost $3 million for a new drug) The Amyloidosis market was $3.6 billion
RHEA-AI
neutral
09/01/23 8:39 AM
Nasdaq : IMMX
managementlow float
Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board
Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical trials for novel agents. Dr. Lentzsch is an internationally recognized expert in multiple myeloma and
RHEA-AI
neutral
08/23/23 8:37 AM
Nasdaq : IMMX
clinical trialfda approvallow float
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma
FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified clinical testing Waiver of the Prescription Drug User Fee (currently at almost $3 million for a new drug) The $13.9 billion Multiple Myeloma market in 2017 is
RHEA-AI
neutral
08/18/23 9:20 AM
Nasdaq : IMMX
managementlow float
Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board
Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center Dr. Landau is a recognized thought leader in CAR-T cell therapy, bone marrow and solid organ transplantation and novel treatment approaches
RHEA-AI
neutral
08/16/23 9:05 AM
Nasdaq : IMMX
clinical triallow float
Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece)
Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that additional NXC-201 clinical data for relapsed/refractory AL
RHEA-AI
negative
07/17/23 9:37 AM
Nasdaq : IMMX
clinical triallow float
Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial
Tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory metastatic colorectal cancer and received 8 median lines of therapy prior to IMX-110 + tislelizumab
RHEA-AI
neutral